Clinical Trials - April 24, 2020
Positive results from AstraZeneca Lynparza trial
AstraZeneca and MSD have announced positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal agent (NHA) treatments (e.g. enzalutamide and abiraterone). Results from the trial showed a […]
New Market - March 30, 2020
AstraZeneca’s Imfinzi approved in the US for extensive small cell lung cancer
AstraZeneca’s Imfinzi has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide plus either carboplatin or cisplatin (platinum-etoposide). The approval by the Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing […]
Collaboration - March 25, 2020
AstraZeneca collaborates with Silence Therapeutics
AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases. This multi-target collaboration will harness Silence’s established siRNA platform to identify and progress liver-based targets, as well as developing new delivery approaches for targeting other tissues such as the […]
COVID-19 - March 24, 2020
AstraZeneca to donate 9 million face masks to support healthcare workers
AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZeneca has partnered with the World Economic Forum’s COVID Action Platform, created with the support of the World Health Organisation, to identify countries in greatest need. Italy will receive the first […]
Pharma Business - March 19, 2020
AstraZeneca’s Lynparza granted orphan drug designation in Japan
Lynparza has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer. Lynparza is co-developed and co-commercialised with MSD. “Japan has the fifth-highest incidence of pancreatic cancer worldwide and patients have seen limited treatment advances over the last few decades. This designation is an important […]
Business article - March 5, 2020
Katarina Ageborg among the Swedish business sector’s most powerful women
Dagens Industri has listed the Swedish business sector’s most powerful women. Among them are a few that operates within life sciences, such as AstraZeneca’s CEO, Katarina Ageborg. The magazine has listed 125 women who has a great power to develop their companies and organizations and hence, develop the whole society towards a more equal business […]
